The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of C4 Therapeutics Inc (NASDAQ: CCCC) was $1.4 for the day, down -7.89% from the previous closing price of $1.52. In other words, the price has decreased by -$7.89 from its previous closing price. On the day, 8.24 million shares were traded. CCCC stock price reached its highest trading level at $1.55 during the session, while it also had its lowest trading level at $1.4.
Ratios:
Our analysis of CCCC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.70 and its Current Ratio is at 5.70. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Upgraded its rating to Overweight and sets its target price to $12 from $8 previously.
On November 18, 2024, Stephens started tracking the stock assigning a Equal-Weight rating and target price of $4.
JP Morgan Upgraded its Underweight to Neutral on January 29, 2024, while the target price for the stock was maintained at $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share. On Nov 18 ’24, another insider, Salter Malcolm, who serves as the Director of the company, bought 13,000 shares for $4.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 99409944 and an Enterprise Value of -51311084. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.50 while its Price-to-Book (P/B) ratio in mrq is 0.51. Its current Enterprise Value per Revenue stands at -1.29 whereas that against EBITDA is 0.447.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.97, which has changed by -0.7113402 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $7.66, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -5.89%, while the 200-Day Moving Average is calculated to be -58.82%.
Shares Statistics:
CCCC traded an average of 1.09M shares per day over the past three months and 1651160 shares per day over the past ten days. A total of 70.99M shares are outstanding, with a floating share count of 54.24M. Insiders hold about 23.61% of the company’s shares, while institutions hold 80.35% stake in the company. Shares short for CCCC as of 1749772800 were 6375598 with a Short Ratio of 5.85, compared to 1747267200 on 6357362. Therefore, it implies a Short% of Shares Outstanding of 6375598 and a Short% of Float of 9.6999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for C4 Therapeutics Inc (CCCC) is a result of the insights provided by 4.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.38 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.52 and -$1.79 for the fiscal current year, implying an average EPS of -$1.63. EPS for the following year is -$1.63, with 4.0 analysts recommending between -$1.36 and -$2.2.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $36.3M, while the lowest revenue estimate was $7.24M, resulting in an average revenue estimate of $22.37M. In the same quarter a year ago, actual revenue was $35.58M
